Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.

Journal of clinical psychopharmacology - 1 Apr 2001

Lessard E, Yessine M A, Hamelin B A, Gauvin C, Labbé L, O'Hara G, LeBlanc J, Turgeon J

Abstract excerpt

CYP2D6 is the major enzyme involved in the metabolism of venlafaxine. Subjects with a low CYP2D6 activity have increased plasma concentrations of venlafaxine that may predispose them to cardiovascular side effects. In vitro and in vivo studies showed that diphenhydramine, a nonprescription antihi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analysis of Variance
Share to Antidepressive Agents, Second-Generation
Share to Cyclohexanols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Drug Interactions

Share to Enzyme Inhibitors

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 11270914
DOI: 10.1097/00004714-200104000-00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11270914-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.PMID 11270914Read ↗

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Semantic proximity Read ↗

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.Semantic proximity Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

Effect of venlafaxine on imipramine metabolism.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.Semantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.Semantic proximity Read ↗

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.